BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)

BIOLOGICAL2 trials

Sponsors

International Vaccine Institute

Conditions

COVID-19 DiseaseCovid19

Phase 2

Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines

International Vaccine InstituteCovid19

Start: 2021-12-29End: 2024-02-28Updated: 2023-04-19

Phase 3

Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

International Vaccine InstituteCOVID-19 Disease

Start: 2021-10-01End: 2024-09-30Target: 8825Updated: 2021-08-16

Related Papers

Immunogenicity and Safety of Heterologous <i>Versus</i> Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique

Clinical Infectious Diseases2025-06-15